KaNDy Therapeutics is a clinical-stage company based in Stevenage, England, focused on developing NT-814 as a non-hormonal treatment for menopausal vasomotor and related symptoms. NT-814 is an oral once-daily small molecule that is a potent, selective dual antagonist of the neurokinin-1 and neurokinin-3 receptors. The company reported positive Phase Ib/IIa proof-of-concept data showing rapid and profound reductions in frequency and severity of hot flashes and nighttime awakenings at effective doses. Proceeds from the recent financing are earmarked to advance NT-814 into a multi-country Phase 2b dose-ranging study. That Phase 2b is due to start recruiting in Q4 2018 in the US, Canada and the UK, with headline results expected in late 2019. Management frames NT-814 as a potential alternative to hormone replacement therapy for millions of women worldwide.

Total raised

$32M

Funding rounds

1

Latest round

Series C

Latest activity

Aug 2018